Work

Plasma ST2 Concentrations Predict Acute Gvhd Development and Non-Relapse Mortality

Year: 2013

Type: article

Study design: Observational Study

Abstract: Acute GVHD is the primary limitation of allogeneic HSCT. We have previously reported that plasma concentrations of suppressor of tumorigenicity 2 (ST2) at the onset of GVHD therapy predicted response at day (D) 28 and non-relapse mortality (NRM) at D180 after therapy initiation. We hypothesized that ST2 measured early in HSCT would predict GVHD occurrence by D100 and D180 NRM after HSCT.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.11.086

Authors: Mark Vander Lugt, Thomas Braun, Samir Hanash, James L.M. Ferrara, Jerome Ritz, Vincent T. Ho, Joseph H. Antin, Qing Zhang, Alice Chin, Aurelie Gomez, Andrew C. Harris, John E. Levine, Sung Won Choi, Daniel R. Couriel, Pavan Reddy, Sophie Paczesny

Institutions: University of Michigan, Fred Hutch Cancer Center, Dana-Farber Cancer Institute

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

Funders: Children's National Hospital, National Institutes of Health, National Cancer Institute

OpenAlex ID: W2103082399

FWCI:

Cites:

Cited by:

Related to: 10